Drug Trial Radar · NCT05714839
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
123
Planned (sponsor's estimate)
Start
Jun 14, 2023
Primary completion
Aug 3, 2028
Study completion Aug 3, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study consists of three parts: * Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). * Part 2: The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different doses of belantamab in combination with a fixed dose of Belantamab mafodotin (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). * Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the belantamab in combination with the pomalidomide-dexamethasone (Pd) standard of care (SoC) backbone. The study will focus on participants with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.
Conditions
- Multiple Myeloma
Interventions
BelantamabDrug
Belantamab will be administered.
Belantamab mafodotinDrug
Belantamab mafodotin will be administered.
PomalidomideDrug
Pomalidomide will be administered.
DexamethasoneDrug
Dexamethasone will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1, 2 and 3: Number of Participants with any Adverse EventTime frame: Up to 52 months
- Part 1 (Dose escalation cohort) and Part 2: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: Cycle 1 (Each cycle is of 28 days)
- Part 1, 2 and 3: Number of Participants with Worst Case Grade Change from Baseline in Laboratory and Vital Sign ParametersTime frame: Up to 52 months
- Part 2: Number of Participants with severity of ocular events by the Keratopathy Visual Acuity (KVA) scaleTime frame: Up to 52 months
- Part 2: Overall Response Rate (ORR)Time frame: Up to 52 months
- Part 3: Very Good Partial Response and better rate (VGPR+)Time frame: Up to 52 months
Locations
59 sites in 15 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Bullhead City, Arizona · Recruiting
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
Pembroke Pines, Florida · Recruiting
GSK Investigational Site
Boston, Massachusetts · Recruiting
GSK Investigational Site
Grand Rapids, Michigan · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Chapel Hill, North Carolina · Recruiting
GSK Investigational Site
Wilson, North Carolina · Recruiting
GSK Investigational Site
Canton, Ohio · Recruiting
GSK Investigational Site
Chattanooga, Tennessee · Recruiting
GSK Investigational Site
Nashville, Tennessee · Recruiting
GSK Investigational Site
Fort Worth, Texas · Recruiting
GSK Investigational Site
Capital Federal, Argentina · Recruiting
GSK Investigational Site
Ciudadela, Argentina · Completed
GSK Investigational Site
Rosario, Argentina · Recruiting
GSK Investigational Site
San Juan Bautista, Argentina · Recruiting
GSK Investigational Site
Viedma, Argentina · Recruiting
GSK Investigational Site
Monte Grande, Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Fitzroy, Victoria, Australia · Recruiting
GSK Investigational Site
Nedlands, Western Australia, Australia · Completed
GSK Investigational Site
Joinville, Brazil · Recruiting
GSK Investigational Site
Salvador, Brazil · Recruiting
GSK Investigational Site
São Paulo, Brazil · Recruiting
GSK Investigational Site
Guangzhou, China · Recruiting
GSK Investigational Site
Suzhou, China · Recruiting
GSK Investigational Site
Helsinki, Finland · Recruiting
GSK Investigational Site
Kuopio, Finland · Recruiting
GSK Investigational Site
Tampere, Finland · Recruiting
GSK Investigational Site
Turku, Finland · Recruiting
GSK Investigational Site
Dresden, Germany · Recruiting
GSK Investigational Site
Beersheba, Israel · Recruiting
GSK Investigational Site
Haifa, Israel · Recruiting
GSK Investigational Site
Jerusalem, Israel · Recruiting
GSK Investigational Site
Petah Tikva, Israel · Recruiting
GSK Investigational Site
Ramat Gan, Israel · Recruiting
GSK Investigational Site
Tel Aviv, Israel · Recruiting
GSK Investigational Site
Aomori, Japan · Recruiting
GSK Investigational Site
Chiba, Japan · Recruiting
GSK Investigational Site
Ehime, Japan · Recruiting
GSK Investigational Site
Kanagawa, Japan · Recruiting
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.